Join Now

Yearly Archives: 2026

TWO YEAR DATA ON EDWARDS LIFESCIENCES’ EVOQUE SYSTEM CONTINUE TO DEMONSTRATE SIGNIFICANT AND SUSTAINED PATIENT BENEFITS

TRISCEND II randomized trial data presented at ACC show lower mortality with EVOQUE system, when accounting for patient crossover NEW ORLEANS–(BUSINESS WIRE)– Edwards Lifesciences (NYSE: EW) today announced new data on the EVOQUE transcatheter tricuspid valve replacement (TTVR) system at the American College of Cardiology Annual Scientific Session (ACC.26), demonstrating significant and sustained patient benefits […]

Posted in BioUtah News | Comments Off on TWO YEAR DATA ON EDWARDS LIFESCIENCES’ EVOQUE SYSTEM CONTINUE TO DEMONSTRATE SIGNIFICANT AND SUSTAINED PATIENT BENEFITS

SINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle Implant

Via OrthoSpineNews   Major clinical milestone marks SINTX’s entry into the foot and ankle reconstruction market and advances commercialization of its silicon nitride biomaterial platform SALT LAKE CITY, Utah, March 19, 2026 (GLOBE NEWSWIRE) — SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced ceramic biomaterials and silicon nitride medical device innovation, […]

Posted in BioUtah News | Comments Off on SINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle Implant

Co-Diagnostics Joint Venture CoMira Receives Approval for Manufacturing Facility in Kingdom of Saudi Arabia’s Sudair Industrial City

Facility in Sudair Industrial City is expected to position CoMira among the early domestic manufacturers of molecular diagnostic testing solutions in Saudi Arabia SALT LAKE CITY, April 2, 2026 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (“Co-Dx” or “the Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoMira […]

Posted in BioUtah News | Comments Off on Co-Diagnostics Joint Venture CoMira Receives Approval for Manufacturing Facility in Kingdom of Saudi Arabia’s Sudair Industrial City

Nelson Labs® Offers Rare Inside Look at Lab Expansion Designed to Help Protect Patient Safety

Salt Lake City–based laboratory opens normally restricted space to invited guests, highlighting the behind‑the‑scenes work that helps keep medicines and medical products safe   SALT LAKE CITY (April 1, 2026) — Nelson Labs, a Salt Lake City–founded global leader in laboratory testing services, recently hosted invited guests for a rare look inside a new cleanroom […]

Posted in BioUtah News | Comments Off on Nelson Labs® Offers Rare Inside Look at Lab Expansion Designed to Help Protect Patient Safety

Fluidx Medical Announces First Patient Treated with Novel Embolic Gel

Gel embolic device designed to simplify the embolization procedure and reduce risks to the patient.

Posted in BioUtah News | Tagged | Comments Off on Fluidx Medical Announces First Patient Treated with Novel Embolic Gel

BioUtah Presents at Medical Korea 2026

BioUtah president & CEO, Kelvyn Cullimoire, was invited by the Korean Health Industry Development Institute (KHIDI), an agency of the Korean Ministry of Health, to present at the Medical Korea conference on March 19-20, 2026. The topic of Cullimore’s presentation was “Why Utah is a preferred landing place for Korean medical device companies desiring to […]

Posted in BioUtah News | Comments Off on BioUtah Presents at Medical Korea 2026

BioUtah CEO, Kelvyn Cullimore, Makes the Rounds in DC

BioUtah CEO, Kelvyn Cullimore, Makes the Rounds in DC

Posted in BioUtah News | Tagged | Comments Off on BioUtah CEO, Kelvyn Cullimore, Makes the Rounds in DC

Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)

First new FDA-approved treatment option in nearly 20 years for families living with this rare lysosomal storage disease.

Posted in BioUtah News | Tagged | Comments Off on Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)

BIOUTAH JOINED NATIONAL CONVENING ON AMERICA’S BIOTECH MOMENT

Biotech is playing an increasingly important role in U.S. economic competitiveness and national security, and Utah plays a key role in contributing to the strength of the American biotech ecosystem.

Posted in BioUtah News | Comments Off on BIOUTAH JOINED NATIONAL CONVENING ON AMERICA’S BIOTECH MOMENT

Kolosis BIO® Expands Surgical Biologics Portfolio with Launch of APEXecm™

The addition of APEXecm reflects Kolosis’s continued commitment to developing and commercializing best-in-class solutions for the surgical community

Posted in BioUtah News | Tagged | Comments Off on Kolosis BIO® Expands Surgical Biologics Portfolio with Launch of APEXecm™

Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer

Approval reinforces Myriad’s leadership in comprehensive HRD testing and establishes MyChoice CDx as the only FDA-approved companion diagnostic for Zejula in the U.S.

Posted in BioUtah News | Tagged | Comments Off on Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer

Merit Medical Launches the Resilience Through-the-Scope Esophageal Stent

New Resilience™ deployment system, anti-migration stent design, and unique stent sizes offer physicians control while enhancing treatment for patients with esophageal fistulas and malignant strictures

Posted in BioUtah News | Tagged | Comments Off on Merit Medical Launches the Resilience Through-the-Scope Esophageal Stent